Clinical trials: Fat; Liver
Metabolic Dysfunction-associated Fatty Liver Cirrhosis
Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Fuzheng Huayu Tablets in patients with metabolic dysfunction-associated fatty liver cirrhosis…
- Trial name
- NCT07663643
- Testing
- Fuzheng Huayu Tablets
- Volunteers
- 459 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Non Alcoholic Fatty Liver
Oral Dietary Fucoxanthin Rich Supplement for Liver Health
Blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with fucoxanthin will decrease biochemical clinical markers related to liver health.
- Trial name
- NCT03625284
- Testing
- FucoVital
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Algatechnologies Ltd.
Healthy
Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)
The purpose of this study is to investigate the metabolic consequences of a moderate weight gain and if the type of dietary fat (saturated versus polyunsaturated) can modify the effects in young healthy adults.
- Trial name
- LIPOGAIN (NCT01427140)
- Testing
- Polyunsaturated fatty acid group, Saturated fatty acid group
- Where
- Sweden
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Fatty Liver, Liver Fibrosis
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- EDACN (NCT00885313)
- Testing
- DHA250, DHA500, Lifestyle intervention
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
- Trial name
- NCT05728697
- Testing
- Endoscopic ultrasound shear wave elastography
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Obesity
Characterization of Serum Proteome in Young Obese Subjects (POSING)
With the project proposal we aim to identify serum markers for the characterization of steatosis in subjects affected by essential obesity at a young age.
- Trial name
- POSING (NCT05761210)
- Testing
- Blood sample collection
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- Istituto Auxologico Italiano
Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum…
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease, Hepatic Steatosis
- Trial name
- NCT06352697
- Testing
- Probiotic lysate (postbiotic and metabiotc)
- Where
- 5 sites in Ukraine
- Volunteers
- 52 people
- Sponsor
- Bogomolets National Medical University
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Alcoholic Steatohepatitis (NASH)
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04140123
- Testing
- ZSP1601
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
NAFLD
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
- Trial name
- NCT03744182
- Testing
- HM15211
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Liver Fibrosis, Fatty Liver
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis…
- Trial name
- NCT06051669
- Testing
- iLivTouch, FibroScan
- Where
- 4 sites in United States
- Volunteers
- 418 people
- Sponsor
- New Discovery LLC
Non-alcoholic Fatty Liver Disease
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver.
- Trial name
- NCT02006498
- Testing
- Sillymarin
- Where
- Malaysia
- Volunteers
- 99 people
- Sponsor
- University of Malaya
Liver Transplant; Complications, Diabete Mellitus
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of…
- Trial name
- Sema-Lit (NCT06060392)
- Testing
- Semaglutide Pill
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Medanta, The Medicity, India
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Affecting approximately one-third of the United States (U.S.) population, the prevalence of NAFLD increases to 90% in patients with…
- Conditions
- Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound
- Trial name
- NCT04820036
- Testing
- Insulin Resistance, Quality of Life Assessment, Liver Function Test
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Non-Alcoholic Steatohepatitis
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
- Trial name
- NCT02571192
- Testing
- SHP626, 5.95 μCi RAD
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Metabolic Associated Fatty Liver Disease
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients.
- Trial name
- NCT05782972
- Testing
- dapagliflozin (Forxiga)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Non-Alcoholic Steatohepatitis(NASH)
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity.
- Trial name
- NCT00706537
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease
This is a single-center, randomized, open-label, controlled clinical trial to compare the effects of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) versus insulin glargine 100 U/mL (iGlar) on…
- Trial name
- NCT07274644
- Testing
- iGlarLixi, IGlar U100
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
MASLD
Structured Physical Activity Intervention in Patients With MASLD Receiving a Mediterranean Diet
Lifestyle interventions based on diet and physical activity are the cornerstone of management for metabolic dysfunction-associated steatotic liver disease (MASLD), yet individual responses remain highly variable.
- Trial name
- EHMet-DIA (NCT07478588)
- Testing
- Exercise plus Mediterranean diet, At-home exercise plus Mediterranean diet
- Where
- 2 sites in Spain
- Volunteers
- 96 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or…
- Trial name
- NCT04235205
- Testing
- Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- Where
- Japan
- Volunteers
- 102 people
- Sponsor
- Yokohama City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.